

# CITATION REPORT

List of articles citing

**Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart**

**DOI: 10.1161/01.res.0000066853.09821.98**  
**Circulation Research, 2003, 92, 595-7.**

**Source:** <https://exaly.com/paper-pdf/35690986/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
213	Cardiovascular effects of sildenafil in experimental ischemia/reperfusion (reply toildenafil-induced cardioprotection in rabbits, by Kukreja, R.C., Ockaili, R., Salloum, F., Xi, L.) <b>2003</b> , 60, 702-703		1
212	Sildenafil-induced cardioprotection in rabbits. <b>2003</b> , 60, 700-1; author reply 702-3		17
211	Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. <b>2004</b> , 286, H1455-60		63
210	Role of apoptosis in reperfusion injury. <b>2004</b> , 61, 414-26		305
209	Opening of Ca <sup>2+</sup> -activated K <sup>+</sup> channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. <b>2004</b> , 287, H2070-7		68
208	Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. <b>2004</b> , 141, 549-51		35
207	Sildenafil citrate alleviates pulmonary hypertension after hypoxia and reoxygenation with cardiopulmonary bypass. <b>2004</b> , 199, 607-14		11
206	Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. <b>2004</b> , 36, 165-73		131
205	The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. <b>2005</b> , 128, 3065-73		31
204	Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection. <b>2005</b> , 1042, 403-18		54
203	HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. <b>2005</b> , 289, H542-8		167
202	Effects of sildenafil citrate on hepatic function and regeneration in normal and alcohol-fed rats. <b>2005</b> , 25, 913-9		8
201	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). <b>2005</b> , 59, 680-91		61
200	Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. <b>2005</b> , 106, 147-62		140
199	Nitric oxide and penile erectile function. <b>2005</b> , 106, 233-66		163
198	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. <b>2005</b> , 42, 219-32		155
197	Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. <i>Cardiovascular Drugs and Therapy</i> , <b>2005</b> , 19, 23-31	3.9	40

196	Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. <b>2005</b> , 5, 10	43
195	Effect of sildenafil citrate on the cardiovascular system. <b>2005</b> , 38, 1303-11	8
194	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. <b>2005</b> , 112, 2642-9	142
193	Sildenafil and endothelial dysfunction in humans. <b>2005</b> , 111, 721-3	22
192	Endothelium-derived nitric oxide regulates postischemic myocardial oxygenation and oxygen consumption by modulation of mitochondrial electron transport. <b>2005</b> , 111, 2966-72	105
191	Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. <b>2005</b> , 280, 12944-55	272
190	Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. <b>2005</b> , 57, 22-7	42
189	Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. <b>2005</b> , 111, 1601-10	280
188	Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. <b>2005</b> , 39, 681-9	39
187	Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. <b>2006</b> , 15, 733-42	26
186	Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. <b>2006</b> , 70, 231-9	100
185	The ubiquitous role of nitric oxide in cardioprotection. <b>2006</b> , 40, 16-23	356
184	Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. <i>Cardiovascular Drugs and Therapy</i> , <b>2006</b> , 20, 27-36	3.9 37
183	Synergistic effects of atorvastatin and sildenafil in cardioprotection--role of NO. <i>Cardiovascular Drugs and Therapy</i> , <b>2006</b> , 20, 5-8	3.9 5
182	The emerging role for type 5 phosphodiesterase inhibition in heart failure. <b>2006</b> , 3, 123-8	12
181	Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. <b>2006</b> , 45, 91-5	51
180	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. <b>2006</b> , 542, 141-7	30
179	Cardioprotection with sildenafil: implications for clinical practice. <b>2006</b> , 13, 3155-64	16

178	Cardiovascular effects of phosphodiesterase 5 inhibitors. <b>2006</b> , 12, 3485-94		45
177	Mechanism of reactive oxygen species generation after opening of mitochondrial KATP channels. <b>2006</b> , 291, H2041-3		10
176	Inhibition of proinflammatory tumor necrosis factor- $\alpha$ -induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: The involvement of soluble guanylate cyclase and protein kinase G. <b>2006</b> , 70, 977-85		36
175	Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. <i>Circulation Research</i> , <b>2006</b> , 98, 133-40	15.7	142
174	Obligatory role of cardiac nerves and alpha1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs. <i>Circulation Research</i> , <b>2006</b> , 99, 1270-6	15.7	36
173	Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. <b>2006</b> , 290, H1960-8		115
172	Sildenafil extends survival and graft function in a large animal lung transplantation model. <b>2006</b> , 29, 288-93		16
171	Cyclic GMP-dependent protein kinase I $\alpha$ attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. <b>2006</b> , 281, 38644-52		102
170	cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. <i>Circulation Research</i> , <b>2007</b> , 100, 1569-78	15.7	255
169	Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. <b>2007</b> , 76, 915-23		106
168	Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. <b>2007</b> , 27, 1947-54		69
167	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. <b>2008</b> , 294, H1398-406		129
166	Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. <b>2007</b> , 292, H342-7		55
165	Activation of hypoxia-inducible factor-1 via prolyl-4 hydroxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. <b>2007</b> , 293, H1571-80		57
164	Phosphodiesterase type 5: expanding roles in cardiovascular regulation. <i>Circulation Research</i> , <b>2007</b> , 101, 1084-95	15.7	164
163	Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. <i>Journal of Cardiovascular Pharmacology</i> , <b>2007</b> , 50, 670-6	3.1	15
162	Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. <b>2007</b> , 6, 608-13		18
161	Cellular Pathways and Molecular Events in Cardioprotection. <b>2007</b> , 281-315		

160	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <b>2007</b> , 15, 76-86	52
159	Molecular evidence of late preconditioning after sevoflurane inhalation in healthy volunteers. <b>2007</b> , 105, 629-40	32
158	Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. <b>2007</b> , 42, 453-8	105
157	Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. <b>2007</b> , 43, 545-51	16
156	[Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. <b>2007</b> , 31, 52-7	1
155	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. <b>2007</b> , 150, 567-76	42
154	Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. <b>2007</b> , 150, 538-40	22
153	Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. <b>2007</b> , 152, 855-69	129
152	The role of iNOS-derived NO in the antihypertrophic actions of B-type natriuretic peptide in neonatal rat cardiomyocytes. <b>2007</b> , 302, 169-77	5
151	Nonurologic applications of phosphodiesterase type 5 inhibitors. <b>2007</b> , 4, 64-70	1
150	Effect of phosphodiesterase 5 inhibitors on apoptosis and nitric oxide synthases in testis torsion: an experimental study. <b>2008</b> , 24, 205-11	25
149	Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. <b>2008</b> , 20, 2231-6	74
148	Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. <b>2008</b> , 12, 2651-64	66
147	Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. <b>2008</b> , 20, 202-12	104
146	Essential role of mitochondrial Ca <sup>2+</sup> -activated and ATP-sensitive K <sup>+</sup> channels in sildenafil-induced late cardioprotection. <b>2008</b> , 44, 105-13	67
145	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <b>2008</b> , 1, 272-80	43
144	Does sildenafil cause myocardial infarction or sudden cardiac death?. <b>2008</b> , 8, 1-7	18
143	Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. <b>2008</b> , 283, 29572-85	153

142	Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. <b>2008</b> , 105, 7028-33	97
141	Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. <b>2008</b> , 326, 380-7	48
140	Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. <b>2008</b> , 233, 1222-30	36
139	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. <b>2008</b> , 294, H1398-H1406	90
138	Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. <b>2008</b> , 3, e2086	61
137	cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. <b>2009</b> , 330, 884-91	59
136	Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. <b>2009</b> , 36, 657-64	26
135	Endothelial dysfunction in the mesenteric artery and disturbed nonadrenergic noncholinergic relaxation of the ileum due to intestinal ischemia-reperfusion can be prevented by sildenafil. <b>2009</b> , 84, 61-7	6
134	Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. <b>2009</b> , 11, 725-38	37
133	PDE5 inhibitors: in vitro and in vivo pharmacological profile. <b>2009</b> , 15, 3464-75	53
132	Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. <b>2009</b> , 297, H387-91	22
131	ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. <b>2009</b> , 296, H1236-43	110
130	Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. <b>2009</b> , 297, F362-70	90
129	Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. <b>2009</b> , 120, S31-6	123
128	A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. <i>Circulation Research</i> , <b>2009</b> , 104, 572-5	15.7 163
127	Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. <b>2009</b> , 53, 1091-7	19
126	Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. <b>2009</b> , 91, 629-35	64
125	Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. <b>2009</b> , 615, 155-62	28

124	Phosphodiesterase inhibition in heart failure. <b>2009</b> , 14, 255-63	51
123	Nitroglycerin protects small intestine from ischemia-reperfusion injury via NO-cGMP pathway and upregulation of alpha-CGRP. <b>2009</b> , 13, 478-85	11
122	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. <b>2009</b> , 30, 1-24	45
121	Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium. <b>2009</b> , 430, 30-7	6
120	Therapeutic Promotion of the Human Coronary Collateral Circulation. <b>2009</b> , 305-408	
119	The past, the present and the future of experimental research on myocardial ischemia and protection. <b>2009</b> , 61, 3-12	30
118	Vardenafil reduces testicular damage following ischemia/reperfusion injury in rats. <b>2009</b> , 25, 374-80	41
117	Phosphodiesterase 5 inhibitors: are they cardioprotective?. <b>2009</b> , 83, 204-12	29
116	Dose-dependent effects of sildenafil on post-ischaemic left ventricular function in the rat isolated heart. <b>2010</b> , 62, 346-51	15
115	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. <b>2010</b> , 3, 507-15	38
114	Role of microRNAs in cardiac preconditioning. <i>Journal of Cardiovascular Pharmacology</i> , <b>2010</b> , 56, 581-8	3.1 48
113	Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. <b>2010</b> , 31, 430-8	58
112	Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. <b>2010</b> , 334, 1023-30	80
111	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. <b>2010</b> , 62, 525-63	677
110	Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. <b>2010</b> , 107, 18202-7	116
109	Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury. <b>2010</b> , 299, H827-36	35
108	Inhibition of iNOS protects endothelial-dependent vasodilation in aged rats. <b>2010</b> , 31, 1324-8	28
107	Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart. <b>2010</b> , 48, 310-21	39

106	Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. <b>2011</b> , 11, 287-94	64
105	Delayed cardioprotection by inhaled anesthetics. <b>2011</b> , 25, 1125-40	16
104	Phosphodiesterases as Drug Targets. <b>2011</b> ,	20
103	Phosphodiesterase-5 Inhibitors in Protection Against Doxorubicin-Induced Cardiomyopathy. <b>2011</b> , 243-255	
102	Effects of sildenafil in combination with angiotensin-converting enzyme inhibitor on limiting infarct expansion in a porcine model of acute myocardial infarction. <b>2011</b> , 146, 459-60	5
101	Rb1 postconditioning attenuates liver warm ischemia-reperfusion injury through ROS-NO-HIF pathway. <b>2011</b> , 88, 598-605	30
100	Phosphodiesterase inhibition in heart failure. <b>2011</b> , 237-49	27
99	Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury. <b>2011</b> , 17, RA44-52	41
98	Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. <b>2011</b> , 6, e27910	20
97	Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. <b>2011</b> , 166, 374-84	50
96	Inhibition of phosphodiesterases leads to prevention of the mitochondrial permeability transition pore opening and reperfusion injury in cardiac H9c2 cells. <i>Cardiovascular Drugs and Therapy</i> , <b>2011</b> , 25, 299-306	3.9 9
95	Sildenafil accelerates fracture healing in mice. <b>2011</b> , 29, 867-73	39
94	Res-erection of Viagra as a heart drug. <b>2011</b> , 4, 2-4	6
93	Effects of vardenafil on testicular torsion/detorsion damage: an experimental study in pigs. <b>2011</b> , 86, 228-32	13
92	Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. <b>2011</b> , 300, H2272-9	58
91	Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. <b>2012</b> , 302, H1347-54	55
90	Phosphodiesterase-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. <b>2012</b> , 5, 653-9	98
89	Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. <b>2012</b> , 125, 2323-33	129



88	Effect of Sildenafil on Heart Nitric Oxide Metabolism and Mitochondrial Function. <b>2012</b> , 169-188	
87	Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. <b>2012</b> , 26, 274-84	34
86	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. <b>2012</b> , 59, 1921-7	58
85	Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. <b>2012</b> , 84, 1045-54	19
84	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <b>2012</b> , 9, 192-9	26
83	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. <b>2012</b> , 7, e45243	65
82	An old drug for a new application: potential benefits of sildenafil in wound healing. <b>2012</b> , 15, 483-98	13
81	Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. <b>2012</b> , 30, 326-35	52
80	Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. <b>2012</b> , 107, 249	24
79	Dose-dependent protective effect of sildenafil citrate on testicular injury after torsion/detorsion in rats. <b>2012</b> , 44 Suppl 1, 300-6	20
78	Dual role of cyclic GMP in cardiac cell survival. <b>2013</b> , 45, 1577-84	6
77	Nitric oxide synthases in heart failure. <b>2013</b> , 18, 1078-99	112
76	Sildenafil after cardiac arrest and infarction; an experimental rat model. <b>2013</b> , 47, 58-64	4
75	Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. <b>2013</b> , 62, 110-6	25
74	Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. <b>2013</b> , 11, 3	47
73	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. <b>2013</b> , 60, 80-8	62
72	Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment. <b>2013</b> , 91, 1055-63	12
71	Therapeutic potential of PDE modulation in treating heart disease. <b>2013</b> , 5, 1607-20	24

70	The safety of preoperative vardenafil in patients undergoing coronary artery bypass graft surgery. <i>Journal of Cardiovascular Pharmacology</i> , <b>2013</b> , 62, 106-9	3.1	3
69	Sildenafil attenuates hepatocellular injury after liver ischemia reperfusion in rats: a preliminary study. <b>2014</b> , 2014, 161942		20
68	Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation. <b>2014</b> , 19, 269-82		16
67	Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. <b>2014</b> , 307, H888-94		16
66	Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication. <b>2014</b> , 5, 328		21
65	Effects of sildenafil on nanostructural and nanomechanical changes in mitochondria in an ischaemia-reperfusion rat model. <b>2014</b> , 41, 763-8		8
64	Tadalafil prevents acute heart failure with reduced ejection fraction in mice. <i>Cardiovascular Drugs and Therapy</i> , <b>2014</b> , 28, 493-500	3.9	18
63	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. <b>2014</b> , 15, 758-67		41
62	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <b>2014</b> , 2014, 257-90		10
61	Diabetic Cardiomyopathy. <b>2014</b> ,		2
60	Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. <b>2014</b> , 85, 408-19		56
59	Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1 $\beta$ signaling. <b>2014</b> , 306, H1558-68		61
58	Clinical and molecular genetics of the phosphodiesterases (PDEs). <b>2014</b> , 35, 195-233		157
57	Vascular endothelial dysfunction and pharmacological treatment. <b>2015</b> , 7, 719-41		120
56	Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. <b>2015</b> , 16, 27015-31		14
55	L-Citrulline Protects Skeletal Muscle Cells from Cachectic Stimuli through an iNOS-Dependent Mechanism. <b>2015</b> , 10, e0141572		29
54	Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. <b>2015</b> , 10, e0143771		15
53	Beetroot juice reduces infarct size and improves cardiac function following ischemia-reperfusion injury: Possible involvement of endogenous H <sub>2</sub> S. <b>2015</b> , 240, 669-81		21

52	Myocardial protection from ischemia-reperfusion injury post coronary revascularization. <b>2015</b> , 13, 1045-57	69
51	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <b>2015</b> , 36, 2565-73	192
50	Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in Podocytes. <b>2015</b> , 290, 12014-26	32
49	Sildenafil activates antioxidant and antiapoptotic genes and inhibits proinflammatory cytokine genes in a rat model of renal ischemia/reperfusion injury. <b>2015</b> , 47, 1907-15	34
48	Strategies to increase nitric oxide signalling in cardiovascular disease. <b>2015</b> , 14, 623-41	312
47	Tadalafil, a Phosphodiesterase Inhibitor Protects Stem Cells over Longer Period Against Hypoxia/Reoxygenation Injury Through STAT3/PKG-I Signaling. <b>2015</b> , 24, 1332-41	9
46	Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. <b>2015</b> , 38, 597-604	8
45	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. <b>2015</b> , 147, 12-21	144
44	The Effect of Sildenafil on Recuperation from Sciatic Nerve Injury in Rats. <b>2016</b> , 33, 204-11	7
43	PDE5 inhibitors protect against post-infarction heart failure. <b>2016</b> , 21, 1194-210	13
42	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. <b>2016</b> , 102, 1750-1756	58
41	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. <b>2016</b> , 111, 154-62	32
40	Preoperative Sildenafil administration in children undergoing cardiac surgery: a randomized controlled preconditioning study. <b>2016</b> , 49, 1403-10	4
39	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <b>2016</b> , 39, 131-42	18
38	PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice. <b>2017</b> , 361, 29-38	5
37	Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors. <b>2017</b> , 17, 445-461	7
36	Sildenafil Postconditioning in a Rat Model of Ventricular Fibrillation/ Resuscitation. <b>2017</b> , 08,	
35	Nitric oxide signalling and neuronal nitric oxide synthase in the heart under stress. <b>2017</b> , 6, 742	23

34	Sildenafil protects neuronal cells from mitochondrial toxicity induced by $\beta$ -amyloid peptide via ATP-sensitive K channels. <b>2018</b> , 500, 504-510	13
33	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <b>2018</b> , 175, 223-231	21
32	Neuroprotective mechanisms of sildenafil and selenium in PTZ-kindling model: Implications in epilepsy. <b>2018</b> , 833, 131-144	17
31	Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia. <b>2018</b> , 9, 289	5
30	Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrenergic and pro-oxidant mechanisms. <b>2019</b> , 149, 60-74	4
29	Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. <b>2020</b> , 34, 353-364	3
28	Cardioprotection of hydralazine against myocardial ischemia/reperfusion injury in rats. <b>2020</b> , 869, 172850	5
27	The vital role for nitric oxide in intraocular pressure homeostasis. <b>2021</b> , 83, 100922	11
26	PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice. <b>2020</b> , 471, 189-201	1
25	cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 75, 516-525	3.1 6
24	Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide. <b>2020</b> , 468, 47-58	7
23	The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. <b>2020</b> , 72, 692-766	53
22	The effect of sesame intake on adult albino rat testis during sildenafil long-term administration. <b>2021</b> , 82,	
21	Sildenafil citrate in healthy and diseased hearts. <b>2021</b> , 6, 033-039	0
20	Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension. <b>2021</b> , 26, 665-676	3
19	cAMP Compartmentalisation and Hypertrophy of the Heart: Good Pools of cAMP and Bad Pools of cAMP Coexist in the Same Cardiac Myocyte. <b>2017</b> , 117-141	1
18	Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. <b>2014</b> , 9, e86977	43
17	Impact of Mitochondrial Ca <sup>2+</sup> -Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. <b>2015</b> , 10, e0144737	34

16	Nitric oxide functions in the heart. <b>2017</b> , 2, 020-026		1
15	Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. <b>2013</b> , 36, 1020-6		11
14	Sildenafil Citrate and Tramadol Administered Separately and in Combination Affects Basal Metabolic Rate, Triiodothyronine (T3) and Cortisol Levels in Albino Wistar Rats. <b>2015</b> , 10, 51-62		4
13	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 1	3.9	1
12	Phosphodiesterase-5 Inhibitors in Cardioprotection. <b>2013</b> , 439-458		
11	PDE-5 Inhibitors in Protection of Diabetic Heart. <b>2014</b> , 323-338		
10	Nitric oxide application for myocardial protection in coronary artery disease. <i>Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya</i> , <b>2019</b> , 34	0.4	
9	Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 76, 684-691	3.1	0
8	Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. <i>Molecular and Cellular Pharmacology</i> , <b>2010</b> , 2, 173-178		17
7	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , <b>2011</b> , 16, e30-5		39
6	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—possible prevention strategy for COVID-19?.		0
5	Endothelial dysfunction: developmental mechanisms and therapeutic strategies. <b>2022</b> , 8, 115-139		0
4	The Effects of Different Doses of Sildenafil on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts. <b>2023</b> , 16, 118		0
3	Nitric Oxide-cGMP-PKG Signaling in the Cardioprotective Effects of Phosphodiesterase 5 Inhibitors. <b>2023</b> , 111-126		0
2	Nitric Oxide in Cardiac Surgery: A Review Article. <b>2023</b> , 11, 1085		0
1	Cardio-Protective Role of a Gut Hormone Obestatin: A Narrative Review. <b>2023</b> ,		0